Inoculation and Mutation
New PhRMA code restrictions bring big changes, but also a chance to adapt
Facebook
Facebook
Twitter
Twitter
LinkedIn
LinkedIn
Email
Email
0 Comments
Comments
Shevin-Sandy also emphasized the overall opportunity for growth within the PhRMA code. “For me, I’m not interested in doing five million pens,” she said. “I’m more interested in doing an educational piece where the distributor and supplier can both actually make a little bit of profit, and not have it be a price war against five other suppliers and five other distributors.” The creative challenge was something else she welcomed: “You need to think about how to use the drug, what can be done for the doctor to teach the patient about the drug and how [the patient] cares for themselves afterwards. So there are several different approaches to it.”
0 Comments
View Comments
Related Content
Comments